A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours
To assess the safety and tolerability of SHR-A1921 in patients with advanced solid tumours, to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or recommended phase II dose (RP2D) of SHR-A1921
Advanced Solid Tumours
DRUG: SHR-A1921
Dose Limited Toxicity (DLT), 21 Days (first cycle)|Maximum Tolerable Dose (MTD), 21 Days (first cycle)|Recommended phase II dose (RP2D), Screening up to dose escalation and expansion study completion, appropriately to 1 year|Adverse Events, Incidence and grade of adverse events as assessed by CTCAE v5.0, Screening up to study completion, an average of 1 year
Time to reach maximum concentration (Tmax) of SHR-A1921、total antibody, Screening up to end of treatment, an average of 1 year|Maximum concentration (Cmax) of SHR-A1921、total antibody, Screening up to end of treatment, an average of 1 year|Area under the concentration-time curve from time zero to the time of the last quantifiable time point t (AUC0-t) of SHR-A1921、total antibody, Screening up to end of treatment, an average of 1 year|Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-t) of SHR-A1921、total antibody, Screening up to end of treatment, an average of 1 year|Terminal half-life (t1/2) of SHR-A1921、total antibody, Screening up to end of treatment, an average of 1 year|Total body clearance (CL) of SHR-A1921、total antibody, Screening up to end of treatment, an average of 1 year|Volume of distribution at steady state (Vss) of SHR-A1921、total antibody, Screening up to end of treatment, an average of 1 year|Mean residence time (MRT) of SHR-A1921、total antibody, Screening up to end of treatment, an average of 1 year|Maximum steady-state drug concentration during a dosage interval (Css, max) of SHR-A1921、total antibody, Screening up to end of treatment, an average of 1 year|Minimum steady-state drug concentration during a dosage interval (Css, min) of SHR-A1921、total antibody, Screening up to end of treatment, an average of 1 year|Accumulation ratio (Rac) of SHR-A1921、total antibody, Screening up to end of treatment, an average of 1 year|Anti-drug antibody(ADA) level of SHR-A1921, Screening up to 90 days after the last dose, an average of 1 year|Objective Response Rate (ORR) assessed by site investigator as per RECIST 1.1, Screening up to study completion, an average of 1 year|Duration of Response (DoR) assessed by site investigator as per RECIST 1.1, Screening up to study completion, an average of 1 year|Disease Control Rate (DCR) assessed by site investigator as per RECIST 1.1, Screening up to study completion, an average of 1 year|Progression-Free Survival (PFS) assessed by site investigator as per RECIST 1.1, Screening up to study completion, an average of 1 year|Overall Survival (OS), Screening up to study completion, an average of 1 year
To assess the safety and tolerability of SHR-A1921 in patients with advanced solid tumours, to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or recommended phase II dose (RP2D) of SHR-A1921